Managed the lymphoma Medical Affairs team (6 professionals) across Austria & Switzerland with Imbruvica as the main target asset. Spearheaded the pre-launch strategy for Erleada (prostate cancer), enhancing market readiness. Strengthened KOL engagements and scientific partnerships to advance product positioning and share of voice in a highly competitive environment. Drove medical team excellence through operational readiness and structured performance metrics.

Led the Medical and Field teams (5 direct reports, 10 total) for cardiology (e.g., Nilemdo/Nustendi, Olmetec, Lixiana) and oncology (e.g., ADCs such as Enhertu or Datroway). Developed and implemented scientific strategies supporting product launches and lifecycle management. Member of the Leadership & Compliance committee, ensuring adherence to policies, regulations and pharma code. Overseen material review and final content approvals to maintain high ethical and compliance standards.

Was responsible for the entire specialty care portfolio (e.g. Duodopa in neurology, Zemplar in nephrology, or Lipanthyl in CV). Executed strategic frameworks for Depatux-M (glioblastoma) in rare disease. Led the hematology as well as oncology groups, overseeing 5 Field Medicals. In hematology, initiated and managed early access programs, supporting patient access to innovative treatments with Venclyxto (CLL, AML, MM). Leveraged local clinical data generation efforts, contributing to 1 PMOS and 2 IIS studies approved in 2018.

Managed the specialty care portfolio, including Zemplar (CKD), Lipanthyl (CV), Duodopa (Parkinson’s), Kaletra (HIV), and Lucrin (prostate cancer). Served as the primary scientific liaison for cross-functional brand teams. Established a holistic patient support nurses’ program for Morbus Parkinson in a rare disease area.

Medical Science Liaison & Advisor, Schering-Plough & MSD AG (2009-2010): focused on depression (Remeron), inflammation, allergy, and anesthesia. Scientific Lead & Clin Project Manager, Kuros Biosurgery AG (2006-2008): led drug formulation development and Phase I & II trials in wound healing in partnership with Baxter Healthcare AG. Postdoctoral Research Fellow, University of Texas & Zürich (2003-2006): specialized in renal co-transport membrane protein research involved in osteoporosis of PM women.